Atara Reports Q2 Loss, FDA Type A Meeting Progress, and Cash Runway into Mid-2027
ATRA has more than doubled off its 52-week low of $3.92.
Summary
Atara reported Q2 2026 results with a net loss of $4.8 million and $9.9 million in cash, but extended its cash runway guidance into mid-2027 and announced a productive FDA Type A meeting for tabelecleucel.
Key Events · Earnings and Guidance · ATRA
-
Q2 Net Loss of $4.8M
Atara reported a net loss of $4.8 million, or $0.32 per share, for Q2 2026, compared to net income of $2.4 million in Q2 2025. Revenue fell to $0.6 million from $17.6 million year-over-year.
-
Cash Runway Extended to Mid-2027
Cash, cash equivalents, and short-term investments totaled $9.9 million as of June 30, 2026. Management expects this, combined with cost reductions, to fund operations into mid-2027.
-
FDA Type A Meeting for Tabelecleucel
Atara and partner Pierre Fabre had a productive Type A meeting with the FDA, confirming the opportunity to resubmit the tabelecleucel BLA based on the existing Phase 3 ALLELE trial. A further regulatory update is expected later this quarter.
-
Potential $31M Milestone Payment
Under its commercialization agreement with Pierre Fabre, Atara is eligible to receive a $31 million milestone payment upon FDA approval of the tabelecleucel BLA, plus tiered royalties on net sales.
Analysis · ATRA · Life Sciences
Atara's Q2 results show a net loss of $4.8 million with only $9.9 million in cash, but the company now expects its cash to fund operations into mid-2027, an improvement from prior guidance. The productive FDA Type A meeting for tabelecleucel is a key regulatory milestone that could lead to a BLA resubmission and a potential $31 million milestone payment. The 87% year-over-year reduction in costs and operating expenses reflects aggressive cost-cutting that extends the runway.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATRA was trading at $9.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $83.1M. The 52-week trading range was $3.92 to $19.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.